Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer Scottsdale, AZ

Journey Medical Corporation Appoints Joseph

Benesch as Chief Financial Officer

Scottsdale, AZ - May 1, 2024 -

Journey Medical Corporation ("Journey Medical" or "the Company") (Nasdaq:

DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration

("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced

the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's

Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November

Claude Maraoui, Co-Founder, President and Chief

Executive Officer of Journey Medical, said, "Joe has been an instrumental leader to our finance and accounting team for the past

few years and it will be a seamless transition as he steps into the permanent CFO role. With more than 25 years of experience in the public

and private sectors including the life sciences industry, Joe's in-depth financial and accounting knowledge and pharmaceutical experience

are valuable assets to our company as we focus on our many upcoming milestones, including the potential approval of DFD-29 for the treatment

of rosacea later this year. We look forward to Joe's continued contributions to Journey Medical."

has over 25 years of experience in all aspects of corporate financial leadership and reporting, technical accounting and controls, corporate

controllership, regulatory and public company compliance, treasury and pharmaceutical company operations. Prior to joining Journey Medical,

Mr. Benesch previously served as the Principal Accounting Officer, Vice President and Corporate Controller of Teligent Pharma Inc., a

specialty generic pharmaceutical company, and Corporate Controller of Torrent Pharmaceuticals, a U.S. subsidiary of the Torrent Group,

a multinational pharmaceutical company. Before joining Torrent, he held senior financial management positions of increasing responsibility

from Corporate Controller to Vice President of Finance at Savient Pharmaceuticals, Adare Pharmaceuticals and Edenbridge Pharmaceuticals.

Mr. Benesch began his career in the public accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young working with a diverse

client base. Mr. Benesch is a graduate of Wilkes University where he earned a BA in accounting and is a Certified Public Accountant.

am privileged and honored to continue to lead our finance organization as we seek to drive sustainable value creation for the Company

and our shareholders while helping the many patients treated with our dermatology products," said Mr. Benesch.

About Journey Medical Corporation

Journey Medical Corporation (Nasdaq: DERM) ("Journey

Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription

pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently

markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry

experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands.

Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common

stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and

Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Forward-Looking Statements

This press release may contain

"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words "the

Company", "we", "us" and "our" may refer to Journey Medical. Such statements include, but

are not limited to, any statements relating to our growth strategy and product development programs and any other statements that

are not historical facts. The words "anticipate," "believe," "estimate," "may,"

"expect," "will," "could," "project," "intend," "potential"

and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on

management's current expectations and are subject to risks and uncertainties that could negatively affect our business,

operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those

currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation

and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales

derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an

increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating

income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative

or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any

setback relating to the sale of such products could impair our operating results; competition could limit our products'

commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk

that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties

for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and

integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our

ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29

product candidate and any future product candidates that we may develop, in-license or acquire; clinical drug development is very

expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our

current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours;

risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection

for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks,

or deficiencies in our or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going

concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;

our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental

to our other shareholders; as well as other risks described in Part I, Item 1A, "Risk Factors," in our Annual Report on

Form 10-K for the year ended December 31, 2023, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We

expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements

contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such

statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements

contained in the Private Securities Litigation Reform Act of 1995.

Media Relations Contact: